Detalhe da pesquisa
1.
Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD.
Ann Neurol
; 95(4): 720-732, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38086777
2.
Intravenous immunoglobulin treatment for acute attacks in myelin oligodendrocyte glycoprotein antibody disease.
Mult Scler
; 29(9): 1080-1089, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37431144
3.
Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study).
Mult Scler
; 29(7): 819-831, 2023 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-36786424
4.
[Autoimmune encephalitis-An update]. / Autoimmunenzephalitis ein Update.
Nervenarzt
; 94(6): 525-537, 2023 Jun.
Artigo
Alemão
| MEDLINE | ID: mdl-36515716
5.
Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD.
J Neuroinflammation
; 19(1): 239, 2022 Oct 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36183103
6.
Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders.
Mult Scler
; 28(5): 757-767, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-34379018
7.
Berlin Registry of Neuroimmunological entities (BERLimmun): protocol of a prospective observational study.
BMC Neurol
; 22(1): 479, 2022 Dec 14.
Artigo
Inglês
| MEDLINE | ID: mdl-36517734
8.
Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
J Neuroinflammation
; 18(1): 105, 2021 May 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33933106
9.
Emerging drugs for the treatment of neuromyelitis optica.
Expert Opin Emerg Drugs
; 25(3): 285-297, 2020 09.
Artigo
Inglês
| MEDLINE | ID: mdl-32731771
10.
Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases: COPANMO(G)-Study.
Neurol Neuroimmunol Neuroinflamm
; 10(2)2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36693760
11.
Structure-function correlates of vision loss in neuromyelitis optica spectrum disorders.
Sci Rep
; 12(1): 17545, 2022 10 20.
Artigo
Inglês
| MEDLINE | ID: mdl-36266394
12.
Serum glial fibrillary acidic protein correlates with retinal structural damage in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
Mult Scler Relat Disord
; 67: 104100, 2022 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-36049341
13.
Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease: CHANCENMO Study.
Neurology
; 98(11): e1184-e1196, 2022 03 15.
Artigo
Inglês
| MEDLINE | ID: mdl-35082170
14.
Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder: A Retrospective, Cross-sectional Analysis.
Neurol Neuroimmunol Neuroinflamm
; 9(3)2022 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35217580
15.
Satralizumab in the treatment of neuromyelitis optica spectrum disorder.
Neurodegener Dis Manag
; 11(1): 49-59, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33167776
16.
Anti-aquaporin 4 IgG Is Not Associated With Any Clinical Disease Characteristics in Neuromyelitis Optica Spectrum Disorder.
Front Neurol
; 12: 635419, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-33776892
17.
SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients.
Sci Rep
; 11(1): 10299, 2021 05 13.
Artigo
Inglês
| MEDLINE | ID: mdl-33986412
18.
AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders.
Mult Scler J Exp Transl Clin
; 7(2): 20552173211006862, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34017610
19.
Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders.
Expert Opin Biol Ther
; 20(9): 1061-1072, 2020 09.
Artigo
Inglês
| MEDLINE | ID: mdl-32228250